DUBLIN–(BUSINESS WIRE)–The “Bromodomain Containing Protein 4 (Protein HUNK1 or BRD4) – Drugs In Development, 2021” drug pipelines has been added to ResearchAndMarkets.com’s offering.
Bromodomain Containing Protein 4 (Protein HUNK1 or BRD4) pipeline Target constitutes close to 43 molecules. Out of which approximately 32 molecules are developed by companies and remaining by the universities/institutes. The molecules developed by companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 2, 3, 7, 17 and 3 respectively.
Bromodomain Containing Protein 4 – Drugs In Development, 2021, outlays comprehensive information on the Bromodomain Containing Protein 4 (Protein HUNK1 or BRD4) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.
It also reviews key players involved in Bromodomain Containing Protein 4 (Protein HUNK1 or BRD4) targeted therapeutics development with respective active and dormant or discontinued projects.
Scope
- The report provides a snapshot of the global therapeutic landscape for Bromodomain Containing Protein 4 (Protein HUNK1 or BRD4)
- The report reviews Bromodomain Containing Protein 4 (Protein HUNK1 or BRD4) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Bromodomain Containing Protein 4 (Protein HUNK1 or BRD4) targeted therapeutics and enlists all their major and minor projects
- The report assesses Bromodomain Containing Protein 4 (Protein HUNK1 or BRD4) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Bromodomain Containing Protein 4 (Protein HUNK1 or BRD4) targeted therapeutics
Key Topics Covered:
- Introduction
- Bromodomain Containing Protein 4 (Protein HUNK1 or BRD4) – Overview
- Bromodomain Containing Protein 4 (Protein HUNK1 or BRD4) – Therapeutics Development
- Bromodomain Containing Protein 4 (Protein HUNK1 or BRD4) – Therapeutics Assessment
- Bromodomain Containing Protein 4 (Protein HUNK1 or BRD4) – Companies Involved in Therapeutics Development
- Bromodomain Containing Protein 4 (Protein HUNK1 or BRD4) – Drug Profiles
- Bromodomain Containing Protein 4 (Protein HUNK1 or BRD4) – Dormant Products
- Bromodomain Containing Protein 4 (Protein HUNK1 or BRD4) – Discontinued Products
- Bromodomain Containing Protein 4 (Protein HUNK1 or BRD4) – Product Development Milestones
- Appendix
Companies Mentioned
- AbbVie Inc
- Amgen Inc
- AstraZeneca Plc
- Boehringer Ingelheim International GmbH
- Bristol-Myers Squibb Co
- Bromodomain Pharmaceuticals Inc
- C4 Therapeutics Inc
- Checkpoint Therapeutics Inc
- Constellation Pharmaceuticals Inc
- ConverGene LLC
- CSPC Pharmaceutical Group Ltd
- Epigene Therapeutics Inc
- Kainos Medicine Inc
For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/3x1fs1
Contacts
ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900